Ignite Creation Date:
2025-12-24 @ 4:56 PM
Ignite Modification Date:
2026-01-04 @ 3:52 PM
Study NCT ID:
NCT05386550
Status:
TERMINATED
Last Update Posted:
2025-06-13
First Post:
2022-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Sponsor:
EMD Serono Research & Development Institute, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-06
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-08-27
Completion Date Type:
ACTUAL
First Submit Date:
2022-05-17
First Submit QC Date:
None
Study First Post Date:
2022-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-10
Last Update Post Date:
2025-06-13
Last Update Post Date Type:
ACTUAL